GlassScriptPhysician profile
Mary D Defigard
NPI 1710914791
$2,299.21
in general payments reported to CMS, 2019-2025
36 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $137 · 2021: $68.47 · 2022: $231 · 2023: $203 · 2024: $481 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $393.64 | 2019-2025 | |
| Radius Health, INC. | $234.02 | 2019-2025 | Tymlos |
| Abbvie INC. | $199.92 | 2019-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $120.67 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $118.19 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Medtronic USA, INC. | $115.08 | 2019 | |
| Mylan Specialty L.P. | $110.99 | 2019 | |
| Lilly USA, LLC | $103.76 | 2019-2024 | Mounjaro |
| Exact Sciences Corporation | $100.10 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.11 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $60.43 | 2019 | |
| Lundbeck LLC | $54.44 | 2019-2025 | Rexulti |
| Sanofi Pasteur INC. | $48.34 | 2019-2022 | |
| Amgen INC. | $47.05 | 2022-2023 | Repatha, Otezla |
| Allergan, INC. | $41.90 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Defigard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.